PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
5.62%
Net income growth under 50% of GNPX's 38.58%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
3.20%
Some D&A expansion while GNPX is negative at -54.37%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
22.07%
Less SBC growth vs. GNPX's 69.33%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
81.65%
Slight usage while GNPX is negative at -134.93%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.82%
A yoy AP increase while GNPX is negative at -79.30%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
28.44%
Some yoy usage while GNPX is negative at -175.68%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-17.77%
Negative yoy while GNPX is 106.95%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
18.75%
Operating cash flow growth below 50% of GNPX's 45.72%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-1425.00%
Negative yoy CapEx while GNPX is 175.03%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1425.00%
We reduce yoy invests while GNPX stands at 128.65%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Both yoy lines negative, with GNPX at -99.57%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.